Novavax raises annual revenue forecast on strength of vaccine deals

Core Viewpoint - Novavax has raised its annual revenue forecast for the third time this year, driven by milestone payments from vaccine supply and licensing agreements, particularly with Takeda Pharmaceuticals in Japan [1] Group 1 - The company has increased its revenue outlook, indicating strong performance and confidence in its vaccine-related business [1] - The adjustments in revenue forecast are attributed to successful partnerships and agreements in the vaccine sector [1]